SCHEMBL277746

SCHEMBL277746

CC(=O)NC1CCN(C(=O)c2ccc(C(=O)NN)s2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM5A P29375 1/20 0.45
KMT2A Q03164 2/20 0.42
HDAC1 Q13547 3/20 0.41
HDAC2 Q92769 3/20 0.41
HDAC3 O15379 2/20 0.41
CNR2 P34972 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.38
VNN1 O95497 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
HPGD P15428 1/20 0.38
SMYD3 Q9H7B4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14395809 0.89 L3MBTL3 (0.46) L3MBTL3L3MBTL1KDM5AKMT2AHDAC1
SCHEMBL278101 0.84 L3MBTL3 (0.46) L3MBTL3L3MBTL1KDM5AKMT2AHDAC1
SCHEMBL280089 0.84 ALDH1A1 (0.51) L3MBTL3L3MBTL1KDM5AHDAC1HDAC2
SCHEMBL1587719 0.81 L3MBTL3 (0.47) L3MBTL3L3MBTL1KDM4EALDH1A1POLB
SCHEMBL13006692 0.81 KDM5A (0.53) L3MBTL3L3MBTL1KDM5AKMT2AMEN1
SCHEMBL12265917 0.79 L3MBTL3 (0.46) L3MBTL3L3MBTL1KDM4EALDH1A1POLB
SCHEMBL12265916 0.76 L3MBTL3 (0.79) L3MBTL3L3MBTL1ALDH1A1HPGD
SCHEMBL280182 0.74 ALDH1A1 (0.44) L3MBTL3L3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL1587143 0.74 HPGD (0.58) L3MBTL3L3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL280183 0.73 ALDH1A1 (0.43) L3MBTL3L3MBTL1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
CN-101076519-A Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL IND LTD (JP) 2007-11-21 CN disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL L3MBTL3 1219/4885L3MBTL1 676/4885KDM5A 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.